The nomination committee in Scandinavian Real Heart AB proposes that Magnus Öhman is elected to the board at the next general meeting. Until then, he will be an adjunct to the board. Magnus Öhman has extensive experience from the medical technology industry, including as CEO of St. Jude Medical's Swedish subsidiary within Cardiac Rhythm Management.
The Swedish subsidiary in Cardiac Rhythm Management (CRM) had at the end of Magnus Öhman's time as CEO over 620 employees, of which 200 in research and development, and sales of over SEK 5 billion, of which SEK 900 million from own production. CRM includes products such as pacemakers and defibrillators.
Magnus Öhman currently runs his own consultancy business in leadership and life science and is also chairman of the medical technology company Neosense Technologies AB, focused on reducing mortality and permanent injuries in premature babies. In addition to several roles at St Jude, Magnus Öhman has also been CEO and board member of the Stockholm Technical Institute Foundation, and a mentor in leadership programs.
– "We look forward to welcoming Magnus Öhman to the Board of Directors and taking advantage of his broad expertise, not least on how to build successful growth companies in advanced medical technology for heart disease", says Chairman of the Board Christer Norström.